RARE (Ultragenyx Corp) Indikator likuiditas cepet

The current quick liquidity position of Ultragenyx Pharmaceutical (RARE) demonstrates the company's solvency, with the latest value recorded as 1.49. The firm adheres to ESG standards by optimizing drug logistics for environmental sustainability. The implementation of AI and robotics in bioanalysis is accelerating drug development. A high-tech R&D pipeline ensures the release of unique mRNA therapies to combat the rarest genetic pathologies.

Rasio jangkoan perantara Ultragenyx Pharmaceutical Inc. (RARE): kanggo periode 04.07.2022 - 31.10.2026

Rincian metrik lan analitis perusahaan ultragenyx.com (RARE)

- nilai pasar lan prakiraan target analis:

Bagan rega Ultragenyx Pharma|RARE - Bagan rega target

- indikator valuasi pasar bisnis:

Biji pasar Ultragenyx Pharma|RARE - Total Nilai Bisnis

- indikator kapitalisasi buku:

Aset Bersih saben Siji Saham Ultragenyx|RARE - Nilai Akuntansi Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku ultragenyx.com|RARE - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

Total Utang marang Modal Ultragenyx Pharmaceutical|RARE - Tanggungan utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Ultragenyx|RARE - Utang kumulatif perusahaan|Rasio utang marang kapitalisasi buku Ultragenyx Pharma|RARE - Tanggungan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Ultragenyx|Indikator likuiditas cepet ultragenyx.com

- rincian bathi lan kelipatan pasar:

RARE - Bathi perusahaan

Analisis komprehensif perusahaan:Ultragenyx Pharmaceutical

The quick ratio measures a company's ability to settle short-term debts using its most liquid assets, intentionally excluding hard-to-sell inventories. By utilizing the quick ratio analysis on GURU.Markets, investors assess the financial cushion of Ultragenyx Pharmaceutical (RARE), which is critical for survival amid costly drug development and fierce competition with biotech behemoths for patent superiority.

Pesaing wigati